PBYI

Puma Biotechnology Inc

6.11 USD
-0.40 (-6.14%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Puma Biotechnology Inc stock is up 21.96% since 30 days ago. The next earnings date is Feb 29, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 11 February’s closed higher than January. In the last 1 Unusual Options Trades, there were 1 CALL. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
05 Jan 16:04 21 Jun, 2024 5.00 CALL 356 201

About Puma Biotechnology Inc

Puma Biotechnology, Inc. focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd.